Clinical Trials Logo

Leukemia, Myeloid, Acute clinical trials

View clinical trials related to Leukemia, Myeloid, Acute.

Filter by:

NCT ID: NCT05499611 Recruiting - Clinical trials for Acute Myeloblastic Leukemia

Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia

COALA
Start date: January 27, 2023
Phase:
Study type: Observational

A retrospective study using a new technology will be performed: the Optical Genome Mapping (OGM) on acute myelogenous leukemia (AML) samples stored at the CRB-Cancer of the Bordeaux University Hospital and annotated in the DATAML clinical database. The main objective is to estimate the proportion of AML patients for whom OGM detects at least one additional abnormality compared to conventional techniques. This study will constitute an important step in the validation of COA as a reference technique for cytogenetic analysis in AML, replacing the classical techniques, and could also constitute a first argument for redesigning the prognostic classification of AML.

NCT ID: NCT05488132 Recruiting - Clinical trials for Acute Myeloid Leukemia, in Relapse

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Start date: April 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

NCT ID: NCT05477589 Recruiting - Clinical trials for Stem Cell Transplantation

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

SCRIPT-AML
Start date: June 7, 2022
Phase: Phase 3
Study type: Interventional

It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)

NCT ID: NCT05471700 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to evaluate the safety and efficacy of Azacytidine in combination with Venetoclax in patients with newly diagnosed fit acute myeloid leukemia.

NCT ID: NCT05471323 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Start date: January 14, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).

NCT ID: NCT05470140 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.

NCT ID: NCT05458258 Recruiting - Clinical trials for Acute Myeloid Leukemia

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Start date: March 1, 2023
Phase:
Study type: Observational

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

NCT ID: NCT05457010 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Start date: November 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05453903 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Start date: October 4, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).